FDA Approves Test For Detection Of HER2 Biomarker In Breast Cancer As A Companion Diagnostic For Trastuzumab

July 30, 2020

Cancer Network (7/29, Slater) reports the FDA “approved the VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast cancer and as a companion diagnostic for trastuzumab (Herceptin) therapy.” The test “is designed t...